Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

A number of research firms recently issued reports on RGLS. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Institutional Trading of Regulus Therapeutics

Several institutional investors have recently modified their holdings of RGLS. Creative Planning bought a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at about $26,000. SG Americas Securities LLC acquired a new stake in Regulus Therapeutics during the 3rd quarter valued at approximately $33,000. Jane Street Group LLC bought a new position in Regulus Therapeutics during the 3rd quarter worth approximately $46,000. JPMorgan Chase & Co. lifted its position in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 52,059 shares during the period. Finally, Barclays PLC boosted its stake in shares of Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 62,549 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Trading Down 5.4 %

NASDAQ RGLS opened at $1.41 on Friday. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The firm has a market capitalization of $92.36 million, a price-to-earnings ratio of -1.32 and a beta of 1.60. The firm’s 50 day simple moving average is $1.54 and its 200 day simple moving average is $1.60.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.